Safety & Harm Reduction

At a Glance

Ayahuasca's intrinsic physical toxicity is low, but it carries real, specific dangers — chiefly dangerous interactions with antidepressants and other serotonergic drugs, and heightened risk for people with heart or psychiatric conditions. In practice, most serious harm comes from drug interactions, undisclosed health problems, adulterated brews and unsafe retreats — not the brew itself. Disclose everything; vet your facilitator.

This page collects the safety considerations that matter most for engaging with plant medicine, drawn from peer-reviewed research, harm-reduction organisations, and practitioner experience. It is not comprehensive medical advice.

If you are in crisis or experiencing distress related to a psychedelic experience, contact the Fireside Project support line (US) or your local emergency services.

Medical Contraindications

Ayahuasca has serious, potentially life-threatening interactions with certain medications and conditions. The risks below are real — and they are specific.

Putting this in perspective. Taken on its own, ayahuasca has low physiological toxicity. The estimated lethal dose is roughly 20 times a typical ceremonial dose — a safety margin comparable to or greater than that of alcohol — and a quantity that is in any case very difficult to drink, given the brew's strong emetic effect. On that basis no death has been reliably attributed to a traditional ayahuasca brew (Banisteriopsis caapi with Psychotria viridis) taken alone (Gable, 2007; ICEERS, 2021). A 2024 systematic review of reported adverse events and toxicity reached the same conclusion: the deaths recorded in ceremony settings are typically linked to confounding factors — undisclosed conditions, drug interactions, or non-traditional admixtures — rather than ayahuasca's intrinsic toxicity (White et al., 2024). And the largest real-world study to date, the Global Ayahuasca Survey of over 10,000 drinkers, found acute physical effects such as vomiting and nausea to be very common but usually benign, with adverse effects serious enough to require medical attention comparatively rare (Bouso et al., 2022). This is not reassurance to be careless: the serious risks below are genuine. But they cluster around drug interactions, pre-existing heart or psychiatric conditions, and adulterated or non-traditional brews — not the brew itself. Knowing where the real danger lies is what keeps you safe.

Serotonergic Medications (CRITICAL)

The MAO-inhibiting harmala alkaloids in ayahuasca can combine with serotonergic medications to produce serotonin syndrome — a reaction that can be life-threatening. This is the single most serious and best-documented drug interaction with ayahuasca, and the reason thorough medication screening is non-negotiable (Callaway & Grob, 1998; dos Santos et al., 2017).

Medications that must be discontinued before ceremony — only ever with appropriate medical supervision and a proper washout period:

• SSRIs (fluoxetine/Prozac, sertraline/Zoloft, paroxetine/Paxil, citalopram/Celexa, escitalopram/Lexapro)
• SNRIs (venlafaxine/Effexor, duloxetine/Cymbalta)
• MAOIs (phenelzine, tranylcypromine, moclobemide)
• Tricyclic antidepressants
• St John's Wort
• Tramadol
• Dextromethorphan (in many cough medicines)
• MDMA
• Lithium

Washout periods vary by medication, and some matter more than people expect: the active metabolites of certain SSRIs persist for weeks after the last dose — fluoxetine (Prozac) in particular can require 5–6 weeks (Callaway & Grob, 1998). Never stop psychiatric medication abruptly — work with your prescribing doctor. If a retreat centre does not ask about your medications in detail, that is a serious red flag.

Cardiovascular Conditions

Ayahuasca produces modest, transient rises in heart rate and blood pressure. In controlled human studies the mean increases were about 11 mmHg (systolic), 9 mmHg (diastolic) and 7 bpm, peaking around 40 minutes and returning to baseline by roughly three hours (Riba, 2003). These changes are generally well tolerated by healthy people. But for anyone with serious heart conditions, uncontrolled hypertension, arrhythmias, or a history of stroke, even a modest pressor effect can be hazardous — do not participate without explicit medical clearance.

Psychiatric Conditions

Individuals with a personal or strong family history of:

• Schizophrenia or schizoaffective disorder
• Psychotic episodes
• Bipolar disorder (particularly Type I)

may be at elevated risk of triggering a psychotic episode or destabilising their condition. A systematic review of the reported cases found that psychotic reactions, while uncommon in ritual and experimental settings, cluster in predisposed individuals — and concluded that people with a personal or family history of psychotic illness or non-psychotic mania should avoid hallucinogens (dos Santos et al., 2017; ICEERS, 2021). This is not a blanket prohibition, but it calls for careful evaluation with qualified professionals.

Pregnancy

Ayahuasca and most master plants used in dieta have not been studied for safety during pregnancy or breastfeeding, so the honest position is that the risks are unknown. Several master plants (including Bobinsana) are traditionally regarded as having contraceptive or abortifacient properties. Avoid during pregnancy, breastfeeding, or when trying to conceive.

How to Vet a Retreat Centre

Not all retreat centres are equal. Some are life-changing in the best sense. Others are negligent, exploitative, or dangerous. Key questions to ask:

• Medical screening: Does the centre require a detailed medical questionnaire? Do they ask about medications, psychiatric history, and heart conditions? If they don't screen, don't go.
• Facilitator-to-participant ratio: During ceremony, is there adequate support? A ratio of one facilitator per 4–6 participants is considered good.
• Emergency protocols: What happens if someone has a medical emergency? Is there access to medical care?
• Lineage and training: Who are the healers, and what is their training? Be wary of centres where the "shaman" completed a brief training programme rather than years of traditional apprenticeship.
• Integration support: Does the centre offer post-ceremony integration? The days and weeks afterward are when the real work happens.
• Consent and boundaries: Are there clear policies on physical contact, sexual boundaries, and consent? Abuse does occur in this space.
• Testimonials and reputation: Look beyond the centre's own website — check independent reviews and forums.

Red Flags

• No medical screening or medication questions
• Pressure to participate when you express doubt
• Claims of guaranteed healing or cure
• Sexual contact between facilitators and participants (this is abuse, full stop)
• Administering Toé (Brugmansia) without explicit consent and full disclosure: its principal active compound, scopolamine, is a deliriant — not a psychedelic — and is genuinely dangerous (De Feo, 2004)
• Excessive secrecy about ingredients, dosing, or the healer's background
• No emergency medical plan

Legal Status

Ayahuasca contains DMT, a controlled substance in most jurisdictions:

• United Kingdom: DMT is a Class A substance under the Misuse of Drugs Act 1971. Ayahuasca as a "preparation" containing DMT is treated as Class A. No religious exemption exists (R v Aziz [2012]).
• United States: DMT is Schedule I federally. Religious exemptions exist for the UDV and Santo Daime churches under RFRA (Gonzales v. O Centro, 2006). Some states/cities have decriminalisation measures.
• Peru: Legal, and recognised as cultural patrimony since 2008.
• Brazil: Legal for religious use (UDV, Santo Daime).
• Netherlands: Tolerated until a 2019 Supreme Court ruling reversed the position.

This is not legal advice. Laws change and enforcement varies. Verify the current status in your jurisdiction before engaging with plant medicine.

Harm Reduction Resources

• Fireside Project — Psychedelic peer-support line (US): call or text 62-FIRESIDE
• ICEERS — International Center for Ethnobotanical Education, Research & Service
• Inekawa — Free weekly integration calls
• MAPS — Multidisciplinary Association for Psychedelic Studies

Common Questions

What medications are dangerous with ayahuasca?

Most critically SSRIs, SNRIs and other serotonergic antidepressants (and MAOIs): combined with the brew's MAO-inhibiting vine they can cause serotonin syndrome, which can be fatal (Callaway & Grob, 1998). Many other drugs interact too — disclose everything you take.

How long before ayahuasca should I stop antidepressants?

There is no universal figure and it must be done with a doctor, but serotonergic antidepressants are commonly withdrawn several weeks ahead (longer for long-acting ones such as fluoxetine) because of the serotonin-syndrome risk (Callaway & Grob, 1998). Never stop psychiatric medication abruptly or unsupervised.

Can ayahuasca trigger psychosis?

It can, particularly in people with a personal or family history of schizophrenia, psychosis or bipolar disorder — which is why these are standard contraindications (dos Santos et al., 2017).

Who should not drink ayahuasca?

Anyone on serotonergic or other contraindicated medication, and those with serious heart conditions or a psychosis/bipolar history, are the main groups advised to avoid it (Gable, 2007; dos Santos et al., 2017). Always share your full health history with a qualified facilitator.

Is ayahuasca physically dangerous — has anyone died?

Its intrinsic physiological toxicity is low (Gable, 2007), and no death has been reliably attributed to a traditional brew taken alone (White et al., 2024). Most serious harms cluster around drug interactions, undisclosed health conditions, adulterated brews and unsafe retreat settings rather than the brew itself — a pattern borne out by the Global Ayahuasca Survey of over 10,000 drinkers (Bouso et al., 2022) — which is why vetting and disclosure matter so much.

References

1. Bouso, J.C., Andión, Ó., Sarris, J.J., Scheidegger, M., Tófoli, L.F., Opaleye, E.S., Schubert, V. & Perkins, D. (2022). Adverse effects of ayahuasca: results from the Global Ayahuasca Survey. PLOS Global Public Health 2(11): e0000438. doi:10.1371/journal.pgph.0000438
2. Callaway, J.C. & Grob, C.S. (1998). Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. Journal of Psychoactive Drugs 30(4): 367–369. doi:10.1080/02791072.1998.10399712
3. De Feo, V. (2004). The ritual use of Brugmansia species in traditional Andean medicine in northern Peru. Economic Botany 58: S221–S229. doi:10.1663/0013-0001(2004)58
4. dos Santos, R.G., Bouso, J.C. & Hallak, J.E.C. (2017). Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. Therapeutic Advances in Psychopharmacology 7(4): 141–157. doi:10.1177/2045125316689030
5. Gable, R.S. (2007). Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction 102(1): 24–34. doi:10.1111/j.1360-0443.2006.01652.x
6. ICEERS (2021). Ayahuasca Technical Report. International Center for Ethnobotanical Education, Research & Service. ICEERS report
7. Riba, J. (2003). Human Pharmacology of Ayahuasca (doctoral thesis, Universitat Autònoma de Barcelona); see also Riba et al. (2003), Journal of Pharmacology and Experimental Therapeutics 306(1): 73–83. Full text (TDX)
8. White, E., Kennedy, T., Ruffell, S., Perkins, D. & Sarris, J. (2024). Ayahuasca and dimethyltryptamine adverse events and toxicity analysis: a systematic thematic review. International Journal of Toxicology 43(3): 327–339. doi:10.1177/10915818241230916